TORRANCE, CA – Sakura Finetek USA, Inc. today announced the acquisition of Genemed Biotechnologies Inc.’s (Genemed) tissue-based Advanced Staining business for cancer detection, diagnosis and monitoring. The deal is expected to be closed by December 31st, 2015. Financial terms of the acquisition were not disclosed.
“We are pleased to add Genemed’s highly skilled and expert personnel, production facility and their extensive catalog of antibodies, probes and detection chemistry to Sakura’s product portfolio. The product portfolio offered by Genemed is a perfect complement to Sakura’s hardware and software engineering competency in developing analytical instrumentation. The combination of both companies will create a powerful Advanced Staining solution and builds on Sakura’s commitment to develop innovative SMART automated platforms for our clinical and life science research customers”, said Takashi Tsuzuki, Chief Executive Officer and President, Sakura Finetek USA.
Genemed’s liquid-based molecular testing products were not included in the acquisition and will be spun out as an independent business. Genemed’s tissue-based Advanced Staining business will be integrated into Sakura Finetek with an immediate impact.
“Sakura has a rich history of innovation and market-leading quality instrument systems. Genemed and its employees are excited about the opportunity to link our highly sensitive and specific Advanced Staining products with Sakura’s highly efficient and novel fully automated Advanced Staining platform. ” said Dr. Dean Tsao, Genemed’s founder and Chief Executive Officer.
About Genemed Biotechnologies Inc.
Genemed Biotechnologies Inc., a privately held company founded in 1987 by Dr. Dean Tsao. Based in South San Francisco California, the biotechnology company specializes in the development of antibodies, probes, detection systems and ancillary reagents for immunohistochemistry and in-situ hybridization. In addition, Genemed offers regents for molecular testing. Its products are used for cancer testing in both the clinical and life science research markets.
For over 15 years, Genemed has provided high-quality contract reagent development and manufacturing services to both diagnostics and pharmaceutical companies. In addition, Genemed markets its own brand of antibodies, probes, detection chemistry and ancillary reagents worldwide.
About Sakura Finetek, USA, Inc.
With U.S. offices based in Torrance, California, Sakura Finetek has been the global leader in advancing cancer diagnostics by providing integrated solutions for anatomic pathology and patients through best-in-class innovation, quality and customer care. With a strategic focus on end-to-end automation, Sakura continues to lead the industry in the development and commercialization of automated SMART Histology instrumentation and consumables for anatomic pathology and cytology. Sakura’s system solutions dramatically increase efficiency enabling same-day-diagnosis, make performance for quality and turnaround time predictable for the entire laboratory allowing standardization of processes and results, and allow our customers to increase their competitiveness while significantly improving patient care.
For more information regarding Genemed Biotechnologies Inc. or any Sakura Finetek product, please visit www.sakuraus.com or contact:
Erico von Bueren
Director of Marketing
Sakura Finetek USA, Inc.
1750 W. 214th St.
Torrance, CA 90501, USA
EvonBueren@SakuraUS.com
